Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crinetics Pharmaceuticals Inc
(NQ:
CRNX
)
47.47
-1.16 (-2.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
550,435
Open
48.94
Bid (Size)
46.83 (1)
Ask (Size)
49.98 (1)
Prev. Close
48.63
Today's Range
47.42 - 49.45
52wk Range
15.76 - 53.70
Shares Outstanding
54,026,103
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
May 22, 2024
Via
Benzinga
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
May 22, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+34.13%
+34.13%
1 Month
+9.58%
+9.58%
3 Month
+28.82%
+28.82%
6 Month
+48.39%
+48.39%
1 Year
+116.07%
+116.07%
More News
Read More
18 Analysts Have This To Say About Crinetics Pharmaceuticals
May 14, 2024
Via
Benzinga
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
February 29, 2024
Via
Benzinga
Crinetics Pharmaceuticals: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
Crinetics Pharmaceuticals Earnings Preview
February 27, 2024
Via
Benzinga
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
May 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
March 19, 2024
Via
Benzinga
Exposures
Product Safety
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 19, 2024
Via
Benzinga
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain
March 19, 2024
Via
Investor Brand Network
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
March 19, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
March 19, 2024
Via
Investor's Business Daily
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
March 19, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
March 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 28, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
February 28, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.